Aspire Biopharma Holdings (ASBP) Net Cash Flow (2022 - 2026)
Aspire Biopharma Holdings' (ASBP) quarterly Net Cash Flow came in at $4.9 million in Q1 2026, up 261.39% year-on-year from $1.3 million in Q1 2025, and up 613.9% on a QoQ basis from -$944367.0 in Q4 2025.
Aspire Biopharma Holdings (ASBP) Net Cash Flow (2022 - 2026) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has 5 years of Net Cash Flow data on file, last reported at $4.9 million in Q1 2026.
- On a quarterly basis, Net Cash Flow rose 261.39% year-over-year to $4.9 million in Q1 2026; TTM through Mar 2026 was $4.5 million, a 247.16% increase from a year earlier, with the FY2025 full-year figure at $1.0 million, down 92.74% from the prior year.
- Net Cash Flow for Q1 2026 stood at $4.9 million, up from -$944367.0 in the prior quarter.
- Over the last five years, Net Cash Flow for ASBP reached as high as $4.9 million in Q1 2026 and fell as low as -$1.1 million in Q2 2025.
- Historically, Net Cash Flow has averaged $343873.5 across 5 years, with a median of -$27683.0 in 2024.
- On a YoY basis, Net Cash Flow climbed as much as 56973.59% in 2025 and fell as far as 7216.14% in 2025.
- Year by year, Net Cash Flow stood at -$35870.0 in 2022, then surged by 99.22% to -$280.0 in 2023, then slumped by 4510.0% to -$12908.0 in 2024, then slumped by 7216.14% to -$944367.0 in 2025, then jumped by 613.9% to $4.9 million in 2026.
- Per Business Quant data, the three most recent Net Cash Flow figures were $4.9 million in Q1 2026, -$944367.0 in Q4 2025, and $1.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,921.77 Bn | 66,921.49 Bn | - | 10.56 Mn |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | -2.44 Mn |
| 4 | BeOne Medicines | 471.57 Bn | 466.77 Bn | 1.35 Bn | 224.46 Mn |
| 5 | Vertex Pharmaceuticals | 122.01 Bn | 114.76 Bn | 2.59 Bn | 457.40 Mn |
| 6 | Regeneron Pharmaceuticals | 70.09 Bn | 61.34 Bn | 3.31 Bn | -152.20 Mn |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | - |
| 8 | Argenx Se | 55.86 Bn | 50.68 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.48 Bn | 34.47 Bn | 959.66 Mn | 60.68 Mn |
| 10 | Aspire Biopharma Holdings | 1.07 Mn | -758,151.27 | 5,750.00 | 4.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.85 Mn |
| Mar 31, 2026 | 4.85 Mn |
| Dec 31, 2025 | -944,367.00 |
| Dec 31, 2025 | -944,367.00 |
| Sep 30, 2025 | 1.74 Mn |
| Sep 30, 2025 | 1.74 Mn |
| Jun 30, 2025 | -1.14 Mn |
| Jun 30, 2025 | -1.14 Mn |
| Mar 31, 2025 | 1.34 Mn |
| Mar 31, 2025 | 1.34 Mn |
| Dec 31, 2024 | -12,908.00 |
| Dec 31, 2024 | -12,908.00 |
| Sep 30, 2024 | -3,063.00 |
| Sep 30, 2024 | -3,063.00 |
| Jun 30, 2024 | -27,683.00 |
| Jun 30, 2024 | -27,683.00 |
| Mar 31, 2024 | 36,113.00 |
| Mar 31, 2024 | 36,113.00 |
| Dec 31, 2023 | -280.00 |
| Dec 31, 2023 | -280.00 |